Baldino brings nearly three decades of healthcare leadership experience to EGS as it works to advance the field of advanced endoluminal procedural techniques
SAN MATEO, Calif. (May 1, 2014)–EndoGastric Solutions® (EGS), the leader in endoluminal reconstructive treatment for gastroesophageal reflux disease (GERD), announced today that industry veteran Skip Baldino has been named President and CEO. Mr. Baldino brings nearly three decades of healthcare experience to EGS, including four years as President, Americas for Given Imaging Ltd., a leader in gastrointestinal diagnostics and imaging that Covidien acquired for $860 million in March 2014.
“I’m thrilled to join EGS at this pivotal point in the company’s evolution,” Mr. Baldino said. “It’s clear that patients suffering from GERD need an option beyond palliative medication to mask the symptoms of the condition or invasive surgery to overcorrect the underlying cause. Based on the growing body of clinical evidence, I believe that the TIF® procedure has the potential to bridge that gap, providing a viable, much-needed treatment option for millions of GERD sufferers. I am excited to work with the team at EGS, and collaborate with the company’s customers and their respective societies to utilize the clinical evidence on TIF to further develop the market for endoscopic treatment of GERD.”
Prior to his four years at Given Imaging, Mr. Baldino served as a divisional Vice President for Abbott Laboratories for eight years, during which he held key commercial leadership roles in several Abbott divisions – diabetes care, diagnostics, medical products (corporate), hospital products (now known as Hospira), health systems and specialty products. His experience encompasses various key customer segments, as well as a wide range of product portfolios, product lifecycles, new product launches and integrations. Mr. Baldino graduated with a bachelor’s degree in Marketing from Philadelphia University.
“Skip is an ideal leader to help guide EGS in its mission to advance the field of endoluminal procedural techniques, and introduce an entirely new treatment paradigm for patients,” said Michael Kleine, Chairman of the Board, EndoGastric Solutions. “Through his experience at Given Imaging, he has a deep understanding of digestive diseases and the endoscopy market in the U.S. During his distinguished 26-year career at Abbott Laboratories, Mr. Baldino established an outstanding track record of consistent and high performing financial and organizational success.”
EGS recently released data showing that the TIF procedure can eliminate troublesome regurgitation and inflammation. The company will present additional data at the upcoming Digestive Disease Week®, which runs from May 3 to 6 in Chicago.
“As EGS continues to generate high quality clinical evidence on the TIF procedure, and innovate the EsophyX platform we’re excited to have Skip on board,” said Michael Carusi, EGS board member and General Partner of Advanced Technology Ventures. “The breadth and depth of his commercial experience, as well as his key relationships with surgeons and gastroenterologists, will be vital as the company continues to grow and expand the market for endoluminal procedures to treat GERD.”
Gastroesophageal reflux disease (GERD) is a common gastrointestinal disease that affects nearly 20 percent of the U.S. population. It is a chronic condition in which the gastroesophageal valve (GEV) allows gastric contents to reflux (wash backwards) into the esophagus, causing heartburn and possible injury to the esophageal lining. In the United States (U.S.), GERD is the most common gastrointestinal-related diagnosis physicians make during clinical visits. Some patients may have mild or moderate symptoms of GERD, while others have more severe manifestations causing chronic heartburn, asthma, chronic cough, and hoarse voice or chest pain. Left untreated, GERD can develop into a pre-cancerous condition called Barrett’s esophagus, which is a precursor for esophageal cancer. The first treatment recommendation for patients with GERD is to make lifestyle changes (e.g., diet, scheduled eating times and sleeping positions). Proton pump inhibitor (PPI) medications are commonly used to treat GERD, but there are a variety of health complications associated with long-term dependency on PPIs, and more than 10 million Americans are refractory to PPI therapy and may opt for surgery.
About Transoral Incisionless Fundoplication (TIF® 2.0 procedure) for Reflux
The TIF 2.0 procedure enables an incisionless approach to fundoplication in which a device is inserted through the mouth, down the esophagus and into the upper portion of the stomach. This approach offers patients looking for an alternative to traditional surgery an effective treatment option to correct the underlying cause of GERD. Based on clinical studies, most patients stopped using daily medications to control their symptoms and had their esophageal inflammation (esophagitis) eliminated up to five years after the TIF 2.0 procedure. Additionally, clinical results have demonstrated that concomitant laparoscopic hiatal hernia repair (LHHR) immediately followed by TIF 2.0 procedure is safe and effective in patients requiring repair of both anatomical defects.
Over 25,000 TIF procedures have been performed worldwide. More than 140 peer-reviewed papers have consistently documented the sustained improved clinical outcomes and exemplary safety profile the TIF procedure provides to patients suffering from GERD. For more information, please visit www.GERDHelp.com.
With the support of clinical societies, commercial and federal insurance providers, representing more than 100 million lives, have recognized the value of the TIF 2.0 procedure through recently expanded coverage policies. The TIF 2.0 procedure is a covered benefit for all Medicare beneficiaries across the country.
For the TIF 2.0 procedure, physicians and hospitals can reference CPT Code 43210 EGD esophagogastric fundoplasty. CPT is a registered trademark of the American Medical Association.
About EsophyX® Technology
The EsophyX technology is used to reconstruct the gastroesophageal valve (GEV) and restore its function as a barrier, preventing stomach acids from refluxing back into the esophagus. The device is inserted through the patient’s mouth with direct visual guidance from an endoscope, and enables creation of a 3 cm, 270° esophagogastric fundoplication. The U.S. Food and Drug Administration cleared the original EsophyX device in 2007. The evolving technology, including the latest iteration EsophyX Z+, launched in 2017, enables surgeons and gastroenterologists to use a wide selection of endoscopes to treat the underlying anatomical cause of GERD.
The EsophyX device, with SerosaFuse® fasteners and accessories, is indicated for use in transoral tissue approximation, full thickness plication and ligation in the gastrointestinal tract. It is indicated for the treatment of symptomatic chronic GERD in patients who require and respond to pharmacological therapy. The device is also indicated to narrow the gastroesophageal junction and reduce hiatal hernia ≤ 2 cm in size in patients with symptomatic chronic GERD. Patients with hiatal hernias larger than 2 cm may be included, when a laparoscopic hiatal hernia repair reduces the hernia to 2 cm or less.
About EndoGastric Solutions®
Based in Redmond, Washington, EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop products and procedures to treat gastrointestinal diseases, including the TIF 2.0 procedure—a minimally invasive solution that addresses a significant unmet clinical need. Join the conversation on Twitter: @GERDHelp Facebook: GERDHelp and LinkedIn: EndoGastric Solutions.
# # #
Phone: +1 917-497-2867